Evidence map›Paper›PMID 34181706›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Immunological Correlates of the HIV-1 Replication-Competent Reservoir Size.

Sherazaan D Ismail, Catherine Riou, Sarah B Joseph, Nancie M Archin, David M Margolis, Alan S Perelson, Tyler Cassidy, Melissa-Rose Abrahams, Matthew Moeser, Olivia D Council and 8 more

Open access · greenAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 3 countries.

Sherazaan D IsmailDivision of Medical Virology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Catherine RiouDivision of Medical Virology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Sarah B JosephDepartment of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0001-9603-574X
Nancie M ArchinDepartment of Medicine and UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina,USA.
David M MargolisDepartment of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Alan S PerelsonTheoretical Biology and Biophysics Group, MS K710, Los Alamos National Laboratory, Los Alamos, New Mexico, USA.
Tyler CassidyTheoretical Biology and Biophysics Group, MS K710, Los Alamos National Laboratory, Los Alamos, New Mexico, USA.
Melissa-Rose AbrahamsDivision of Medical Virology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Matthew MoeserLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Olivia D CouncilLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Lyle R McKinnonCentre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
Farzana OsmanCentre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
Quarraisha Abdool KarimCentre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
Salim S Abdool KarimCentre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
Ronald SwanstromDepartment of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Carolyn WilliamsonDivision of Medical Virology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Nigel J GarrettCentre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
Wendy A BurgersDivision of Medical Virology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0003-3396-9398
University of North Carolina at Chapel Hill · USUniversity of Cape Town · ZACentre for the AIDS Programme of Research in South Africa · ZALos Alamos National Laboratory · US

Funding

Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI164567 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2021 to 2026
$31.6M
Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI126619 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARGOLIS, DAVID M. · 2016 to 2020
$23.2M
Spatial Models of Intrahepatic Hepatitis C Virus Propagation in HumansR01AI116868 · NIAID · TRIAD NATIONAL SECURITY, LLC · PI ASHWIN BALAGOPAL, Ruy M Ribeiro · 2016 to 2026
$8.5M
Modeling Viral and T Lymphocyte DynamicsR01OD011095 · OD · TRIAD NATIONAL SECURITY, LLC · PI PERELSON, ALAN S · 2012 to 2024
$5.0M
Immune System Modeling/HIVR01AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 1990 to 2021
$3.7M
Formation of the HIV-1 Latent ReservoirR01AI147849 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SWANSTROM, RONALD I · 2020 to 2024
$3.0M
Modeling the HIV latent reservoir, latency reversal and immunotherapeutics for HIV cureR01AI152703 · NIAID · TRIAD NATIONAL SECURITY, LLC · PI KE, RUIAN · 2020 to 2024
$3.0M
High resolution profiling and computational modeling of influenza virus-immune dynamics during natural infectionU01AI186993 · NIAID · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Christopher Byron Brooke, Ruian Ke · 2025 to 2026
$2.7M
Timing of establishment of the HIV latent reservoir in subtype C infected womenR01AI115981 · NIAID · UNIVERSITY OF CAPE TOWN · PI SWANSTROM, RONALD I, WILLIAMSON, CAROLYN · 2015 to 2019
$1.7M
FIC NIH HHSNIAID NIH HHS R01 AI028433NIAID NIH HHS R01 AI115981NIAID NIH HHS R01 AI116868NIAID NIH HHS R01 AI147849NIAID NIH HHS R01 AI152703NIAID NIH HHS U01 AI186993NIAID NIH HHS UM1 AI126619NIAID NIH HHS UM1 AI164567NIH HHS R01 OD011095NIH HHS UM1 AI126619Wellcome TrustWellcome Trust 203135/Z/16/Z
6 · The paper itself

Abstract

Understanding what shapes the latent human immunodeficiency virus type 1 (HIV-1) reservoir is critical for developing strategies for cure. We measured frequency of persistent HIV-1 infection after 5 years of suppressive antiretroviral therapy initiated during chronic infection. Pretreatment CD8+ T-cell activation, nadir CD4 count, and CD4:CD8 ratio predicted reservoir size.

Indexed as

HIV-1HIV InfectionsAnti-Retroviral AgentsCD4-Positive T-LymphocytesHumansViral LoadVirus LatencyVirus ReplicationAnti-Retroviral AgentsHIV-1replication-competent virusreservoirT-cell activation

Identifiers

PMID34181706
PMCPMC8528395
OpenAlexW3176883758

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.